Phase III TAILOR Landmark Study Demonstrates Significant Benefits of Erbitux in Combination with FOLFOX Over FOLFOX Alone
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Chinese pivotal Phase III study meets its primary endpoint of increased progression-free survival in first-line treatment of patients with RAS wild-type metastatic colorectal cancer - Merck will work with relevant authorities to make ...